Vascular access site complications after percutaneous coronary intervention with abciximab in the evaluation of c7E3 for the prevention of ischemic complications (EPIC) trial

被引:80
作者
Blankenship, JC [1 ]
Hellkamp, AS
Aguirre, FV
Demko, SL
Topol, EJ
Califf, RM
机构
[1] Geisinger Med Ctr, Dept Cardiol, Danville, PA 17822 USA
[2] Duke Clin Res Inst, Durham, NC USA
[3] St Louis Univ, Med Ctr, St Louis, MO USA
[4] Cleveland Clin Fdn, Cleveland, OH 44195 USA
关键词
D O I
10.1016/S0002-9149(97)00796-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thrombolytic therapy or intense anticoagulation during percutaneous transluminal coronary revascularization (PTCR) increases the risk of vascular access site complications. This study evaluated the association of abciximab, a glycoprotein IIb/IIIa receptor blocker, with vascular access site complications after PTCR, Of 2,058 patients who underwent PTCR in the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial, major vascular access site bleeding (a drop in hematocrit >15%), minor vascular access site bleeding (>10% drop), or surgical repair of the access site occurred in 5%, 12%, and 1.4% of all patients, respectively. Minor and/or major bleeding or surgery occurred in 21.8% of abciximab patients, compared with 9.1% of placebo patients (p <0.001). Logistic regression analysis identified these predictors of minor and/or major bleeding and/or surgical repair, in descending order of importance: abciximab therapy, acute myocardial infarction at enrollment, high baseline hematocrit, time in catheterization laboratory, heavier weight, female gender, maximum in catherization laboratory activated clotting time, sheath size, and age (all p <0.05). Vascular access site complications increased median post-PTCR length of stay from 2 days (no bleeding) to 3 days (minor bleeding) and 6 days (major bleeding), Site-to-site variation in vascular access site complications varied six fold. Analyses of subsequent studies of PTCR with abciximab will determine whether discontinuing heparin and removing sheaths early after PTCR reduces the risk of vascular access site complications. (C) 1998 by Excerpta Medica, Inc.
引用
收藏
页码:36 / 40
页数:5
相关论文
共 27 条
[1]   BLEEDING COMPLICATIONS WITH THE CHIMERIC ANTIBODY TO PLATELET GLYCOPROTEIN IIB/IIIA INTEGRIN IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION [J].
AGUIRRE, FV ;
TOPOL, EJ ;
FERGUSON, JJ ;
ANDERSON, K ;
BLANKENSHIP, JC ;
HEUSER, RR ;
SIGMON, K ;
TAYLOR, M ;
GOTTLIEB, R ;
HANOVICH, G ;
ROSENBERG, M ;
DONOHUE, TJ ;
WEISMAN, HF ;
CALIFF, RM .
CIRCULATION, 1995, 91 (12) :2882-2890
[2]  
Blankenship James, 1996, Journal of the American College of Cardiology, V27, p360A
[3]   HEMORRHAGIC EVENTS DURING THERAPY WITH RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR, HEPARIN, AND ASPIRIN FOR ACUTE MYOCARDIAL-INFARCTION - RESULTS OF THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI), PHASE-II TRIAL [J].
BOVILL, EG ;
TERRIN, ML ;
STUMP, DC ;
BERKE, AD ;
FREDERICK, M ;
COLLEN, D ;
FEIT, F ;
GORE, JM ;
HILLIS, LD ;
LAMBREW, CT ;
LEIBOFF, R ;
MANN, KG ;
MARKIS, JE ;
PRATT, CM ;
SHARKEY, SW ;
SOPKO, G ;
TRACY, RP ;
CHESEBRO, JH .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (04) :256-265
[4]   USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].
CALIFF, RM ;
SHADOFF, N ;
VALETT, N ;
BATES, E ;
GALEANA, A ;
KNOPF, W ;
SHAFTEL, J ;
BENDER, MJ ;
AVERSANO, T ;
RAQUENO, J ;
GURBEL, P ;
COWFER, J ;
COHEN, M ;
CROSS, P ;
BITTL, J ;
EDDINGS, K ;
TAYLOR, M ;
DEROSA, K ;
HATTEL, L ;
COOPER, L ;
ESHELMAN, B ;
FINTEL, D ;
NIEMYSKI, P ;
KLEIN, L ;
KENNEDY, H ;
THORNTON, T ;
KEREIAKES, D ;
MARTIN, L ;
ANDERSON, L ;
HIGBY, N ;
ELLIS, S ;
BREZINA, K ;
GEORGE, B ;
CHAPEKIS, A ;
SMITH, D ;
ANWAR, A ;
GERBER, TL ;
PRITCHARD, GL ;
MYLER, R ;
SHAW, R ;
MURPHY, M ;
WARD, K ;
MADIGAN, NP ;
BLANKENSHIP, J ;
HALBERT, M ;
FLANAGAN, C ;
TANNENBAUM, M ;
POLICH, M ;
STEVENSON, C ;
TCHENG, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961
[5]   SAFETY AND EFFICACY OF EXTENDED UROKINASE INFUSION PLUS STENT DEPLOYMENT FOR TREATMENT OF OBSTRUCTED, OLDER SAPHENOUS-VEIN DRAFTS [J].
DENARDO, SJ ;
MORRIS, NB ;
ROCHASINGH, KJ ;
CURTIS, GP ;
RUBENSON, DS ;
TEIRSTEIN, PS .
AMERICAN JOURNAL OF CARDIOLOGY, 1995, 76 (11) :776-780
[7]   A RANDOMIZED COMPARISON OF CORONARY-STENT PLACEMENT AND BALLOON ANGIOPLASTY IN THE TREATMENT OF CORONARY-ARTERY DISEASE [J].
FISCHMAN, DL ;
LEON, MB ;
BAIM, DS ;
SCHATZ, RA ;
SAVAGE, MP ;
PENN, I ;
DETRE, K ;
VELTRI, L ;
RICCI, D ;
NOBUYOSHI, M ;
CLEMAN, M ;
HEUSER, R ;
ALMOND, D ;
TEIRSTEIN, PS ;
FISH, RD ;
COLOMBO, A ;
BRINKER, J ;
MOSES, J ;
SHAKNOVICH, A ;
HIRSHFELD, J ;
BAILEY, S ;
ELLIS, S ;
RAKE, R ;
GOLDBERG, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (08) :496-501
[8]   FLEXIBLE METHODS FOR ANALYZING SURVIVAL-DATA USING SPLINES, WITH APPLICATIONS TO BREAST-CANCER PROGNOSIS [J].
GRAY, RJ .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1992, 87 (420) :942-951
[9]   A PROSPECTIVE, RANDOMIZED TRIAL COMPARING COMBINATION HALF-DOSE TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND STREPTOKINASE WITH FULL-DOSE TISSUE-TYPE PLASMINOGEN-ACTIVATOR [J].
GRINES, CL ;
NISSEN, SE ;
BOOTH, DC ;
GURLEY, JC ;
CHELLIAH, N ;
WOLF, R ;
BLANKENSHIP, J ;
BRANCO, MC ;
BENNETT, K ;
DEMARIA, AN .
CIRCULATION, 1991, 84 (02) :540-549
[10]  
Hong MK, 1996, J INVASIVE CARDIOL, V8, P15